摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-tert-butyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | 442534-20-5

中文名称
——
中文别名
——
英文名称
N-tert-butyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
英文别名
3-methyl-N-(tert-butyl)-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide;N-tert-butyl-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
N-tert-butyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide化学式
CAS
442534-20-5
化学式
C10H14N6O2
mdl
——
分子量
250.26
InChiKey
XDPXPBGSKWFHLP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    92
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-tert-butyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide硫酸 作用下, 反应 3.0h, 以52%的产率得到替莫唑胺
    参考文献:
    名称:
    Identification and Physicochemical Characteristics of Temozolomide Process-Related Impurities
    摘要:
    本文介绍了抗癌治疗剂替莫唑胺(TZ-7)的起始原料 TZ-5 和关键中间体 TZ-6 的晶体结构,以及它们的光谱和热学特征。这两种化合物都在三菱 P-1 空间群中结晶。X 射线晶体学研究证明,化合物 TZ-6 以一水合物的形式存在。1H、13C 和 15N 核磁共振光谱中的信号得到了完整的结构分配,傅立叶变换红外光谱和拉曼光谱也证实了其结构。文章介绍了高纯度 TZ-6 在小规模工厂生产 TZ-7 过程中的重要性,根据 HPLC 方法,TZ-7 的理想多晶型 III 的纯度高于 99.50%。
    DOI:
    10.3390/molecules181215344
  • 作为产物:
    描述:
    2-amino-2-cyano-N-(1,1-dimethylethyl)-acetamide hydrochloride 在 lithium chloride hydrate 、 溶剂黄146 作用下, 以 二氯甲烷 为溶剂, 反应 21.5h, 生成 N-tert-butyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
    参考文献:
    名称:
    Identification and Physicochemical Characteristics of Temozolomide Process-Related Impurities
    摘要:
    本文介绍了抗癌治疗剂替莫唑胺(TZ-7)的起始原料 TZ-5 和关键中间体 TZ-6 的晶体结构,以及它们的光谱和热学特征。这两种化合物都在三菱 P-1 空间群中结晶。X 射线晶体学研究证明,化合物 TZ-6 以一水合物的形式存在。1H、13C 和 15N 核磁共振光谱中的信号得到了完整的结构分配,傅立叶变换红外光谱和拉曼光谱也证实了其结构。文章介绍了高纯度 TZ-6 在小规模工厂生产 TZ-7 过程中的重要性,根据 HPLC 方法,TZ-7 的理想多晶型 III 的纯度高于 99.50%。
    DOI:
    10.3390/molecules181215344
点击查看最新优质反应信息

文献信息

  • Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers
    申请人:Wang Yongfeng
    公开号:US20060047117A1
    公开(公告)日:2006-03-02
    This invention relates to the use of temozolomide esters (4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylate esters) Formula 1 as potent anticancer pro-drugs for treatment of cancers by topical and transdermal applications, and to a novel process for synthesis of temozolomide esters by a direct esterification of temozolomide acid (3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid) with a halogeno-aliphatic compound in presence of a base, or with an alcohol in presence of a dehydrate agent.
    该发明涉及使用替莫唑胺酯(4-二氢-3-甲基-4-氧基咪唑[5,1-d]-1,2,3,5-四唑-8-羧酸酯)化合物(式1)作为有效的抗癌前药,用于局部和经皮应用治疗癌症,并涉及一种新型合成替莫唑胺酯的方法,即通过直接酯化替莫唑胺酸(3,4-二氢-3-甲基-4-氧基咪唑[5,1-d]-1,2,3,5-四唑-8-羧酸)与卤代脂肪化合物在碱的存在下,或与醇在脱剂存在下进行酯化。
  • [EN] TEMOZOLOMIDE ANALOGS AND METHODS OF USE<br/>[FR] ANALOGUES DE TÉMOZOLOMIDE ET PROCÉDÉS D'UTILISATION
    申请人:ST JOHNS CANCER INST
    公开号:WO2022026756A1
    公开(公告)日:2022-02-03
    Disclosed herein are compounds and methods for treating cancer, such as glioblastomas.
    本文揭示了用于治疗癌症(如胶质母细胞瘤)的化合物和方法。
  • Process for preparing temozolomide
    申请人:Turchetta Stefano
    公开号:US20100036121A1
    公开(公告)日:2010-02-11
    Described is a new process for producing temozolomide, comprising the reaction between 5-aminoimidazole-4-carboxamide and N-succinimidyl-N′-methyl carbamate and the subsequent reaction of the thus obtained carbamoyl 5-aminoimidazole-4-carboxamide with sodium nitrite. Temozolomide is then purified by chromatography on adsorbent polymeric resin and subsequent crystallization from water and acetone.
    描述了一种生产替莫唑胺的新工艺,包括5-咪唑-4-羧酰胺与N-琥珀酰亚胺基-N'-甲基氨基甲酸酯之间的反应,并随后将所得的羧酰基5-咪唑-4-羧酰胺与亚硝酸钠反应。然后,通过聚合物树脂吸附层析和随后从丙酮中结晶来纯化替莫唑胺
  • Process for the preparation of temozolomide and analogs
    申请人:Pathi Srinivas Laxminarayan
    公开号:US20090326028A1
    公开(公告)日:2009-12-31
    A process for the preparation of compounds of formula IA, where R═CH 3 (i.e. temozolomide): comprising diazotizing a compound of the formula IIA: where in R is as defined above in the presence of at least one metal halide, an acid and a source of nitrous acid, followed by conversion of acidic solution containing temozolomide. The conversion can be carried out by a liquid-liquid extraction technique in a water immiscible solvent. The temozolomide may be further purified in an acetone-water mixture.
    一种制备式为IA的化合物的方法,其中R═CH3(即特莫唑胺):包括在至少一种属卤化物、酸和亚硝酸源的存在下,重氮化式为IIA的化合物:其中R如上所定义,随后通过液液萃取技术在不溶于的溶剂中转化含特莫唑胺的酸性溶液。特莫唑胺可以在丙酮-混合物中进一步纯化。
  • SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS
    申请人:Kuo Shen-Chun
    公开号:US20090023919A1
    公开(公告)日:2009-01-22
    This invention relates to a novel process for the synthesis of Temozolomide, an antitumor compound, and analogs, and to intermediates useful in this novel process.
    本发明涉及一种新颖的合成抗肿瘤化合物Temozolomide及其类似物的方法,以及在该新颖方法中有用的中间体。
查看更多

同类化合物

米托唑胺 氰基替莫唑胺 替莫唑胺 N-[4-(2-氟苯甲酰)-1,3-二甲基-1H-吡唑-5-基]-N-甲基苯酰胺 3-(2H3)甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N-甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-N,N-二甲基-4-氧代-3,4-二氢咪唑并[5,1-d][1,2,3,5]四嗪-8-甲酰胺 3-(2-氯乙基)-4-氧代-3H-咪唑并(5,1-d)-1,2,3,5-四嗪-8-羧酸 3,4-二氢-3-甲基-4-氧代咪唑并[5,1-D]-1,2,3,5-四嗪-8-甲酰胺酸 8-carbamoyl-3-(2,3-dichloropropyl)-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one 3-(2-bromoethyl)-8-carbamoyl-[3H]-imidazo[5,1-d]-1,2,3,5-tetrazin-4-one 3-(2-((4-fluoro-2-nitrophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-(prop-2-ynyl)-8-(4-(thiophen-3-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(2,4'-bithiazol-2'-yl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methylsulfinylmethyl)-8-(4-(thiophen-3-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methoxymethyl)-8-(4-(thiophen-2-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one N,6-dimethyl-4-oxo-3-(2,2,2-trifluoroethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 3-(methylthiomethyl)-8-(4-(thiophen-3-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methylsulfinylmethyl)-8-(4-(thiophen-2-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-[4-(1,3-Benzodioxol-5-yl)-1,3-thiazol-2-yl]-3-(methoxymethyl)imidazo[5,1-d][1,2,3,5]tetrazin-4-one N-tert-butyl-2-(3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazin-8-yl)thiazole-4-carboxamide 3-methyl-8-(4-(thiophen-3-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-methyl-8-(4-(thiophen-2-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methoxymethyl)-8-(4-(thiophen-3-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methoxymethyl)-8-(4-phenylthiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(4-tert-butylthiazol-2-yl)-3-propargylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one 3-(methylthiomethyl)-8-(4-(thiophen-2-yl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(4-(4-bromophenyl)thiazol-2-yl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methylthiomethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 8-(morpholinosulfonyl)-3-(2,2,2-trifluoroethyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 6-methyl-8-(methylsulfonyl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-methyl-8-(4-phenylthiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(4-ethylthiazol-2-yl)-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 4-oxo-3-(prop-2-ynyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 8-(methylsulfonyl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-((methoxymethylthio)methyl)-N-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 8-[4-(4-methylsulfonylphenyl)thiazol-2-yl]-3-propargylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one N-methyl-4-oxo-3-(2,2,2-trifluoroethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 8-(1-methyl-4-(thiophen-2-yl)-1H-imidazol-2-yl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-methyl-N-(iso-butyl)-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide N,N-dimethyl-4-oxo-3-(2,2,2-trifluoroethyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 3-(methoxymethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide 8-(4-tert-butylthiazol-2-yl)-3-(methoxymethyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 8-(morpholinosulfonyl)-3-(prop-2-ynyl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-(methoxymethyl)-8-(4-(4-(methylsulfonyl)phenyl)thiazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one 3-methyl-8-(1-methyl-1H-benzo[d]imidazol-2-yl)imidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one N,6-dimethyl-3-(methylsulfinylmethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide N-methyl-4-oxo-3-((2,2,2-trifluoroethoxy)methyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-sulfonamide